Replies to post #121017 on Biotech Values

[jq1234]

Correction:

HR 0.37 for Vemurafenib vs dacarbazine.
HR 0.72 for Yervoy plus dacarbazine vs dacarbazine

[genisi]

Vemurafenib [Zelboraf] as monotherapy result is VERY impressive, much more than IPI in combination with dacarbazine on both efficacy and safety. I know it is not exact same patient population, but comparison will inevitablely made:

HR 0.37 for Vemurafenib vs dacarbazine.
HR 0.72 for Yervoy plus dacarbazine vs dacarbazine.

So now patients with an unresectable or metastatic melanoma who are BRAF V600E positive (and their docs), should consider treatment sequence - Zelboraf or Yervoy first. Guess the decision is a lot easier if one's cancer is very advanced and patient is in bad shape.